Provides guidance for managing whistleblower policies in light of the Dodd-Frank Act provisions. This title: includes case studies of GlaxoSmithKline, Pfizer and other high profile whistleblower incidences; examines new Dodd-Frank incentives to whistleblowers; and, more.